Cover Image

Assessing the potential for precision medicine in body weight reduction with regard to type 2 diabetes mellitus therapies: A meta‐regression analysis of 120 randomized controlled trials

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Kris G. Vargas, Tobias Rütten, Benedikt Siemes, Maximilian Brockmeyer, Claudio Parco, Alexander Hoss, Sabrina Schlesinger, Christian Jung, Michael Roden, Malte Kelm, Georg Wolff, Oliver Kuss
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Diabetes, Obesity and Metabolism
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The melanocortin‐4 receptor pathway and the emergence of precision medicine in obesity management
by: Sima Fansa, et al.
Published: (2024)

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
by: Matthew J. Armstrong, et al.
Published: (2024)

Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta‐regression analysis incorporating FLOW and SOUL trials
by: Masashi Hasebe, et al.
Published: (2025)

Association between glycated haemoglobin A 1c and total haemoglobin mass in adults with type 1 diabetes mellitus. A proof‐of‐concept study
by: Janis Schierbauer, et al.
Published: (2025)

Comparative effectiveness of combination therapy with SGLT ‐2 inhibitors and GLP ‐1 RAs compared with SGLT ‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study
by: Gregor A. Maier, et al.
Published: (2026)

Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta‐analysis of randomized controlled trials
by: Gabriel Grando Alves, et al.
Published: (2024)

Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
by: Frederick Berro Rivera, et al.
Published: (2024)

Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes: Design and rationale of the REC1TE trial
by: David S. Mathiesen, et al.
Published: (2025)

Progressive increases in adiposity and ectopic fat surrogates across glycaemic states highlight weight reduction as a key target for type 2 diabetes prevention, especially in younger people
by: Sabrina Scilletta, et al.
Published: (2025)

Five years liraglutide treatment improves glucose tolerance in women with previous gestational diabetes mellitus—Results from a randomised controlled trial
by: Emilie S. Andersen, et al.
Published: (2025)

Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme
by: Brandon K. Bergman, et al.
Published: (2025)

Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT ‐1 to ‐4 trials
by: Domenica M. Rubino, et al.
Published: (2025)

Immunogenicity, efficacy and safety of a biosimilar insulin glulisine compared with originator in adults with type 1 diabetes mellitus: A phase III randomised clinical trial
by: Roman Drai, et al.
Published: (2025)

Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial
by: Da Hea Seo, et al.
Published: (2025)

An open‐label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerability
by: Esther Latres, et al.
Published: (2025)

Efficacy and safety of imeglimin add‐on to DPP ‐4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double‐blind FAMILIAR trial
by: Kohei Kaku, et al.
Published: (2025)

Evaluating different low‐density lipoprotein cholesterol thresholds to initiate statin for prevention of cardiovascular diseases in patients with type 2 diabetes mellitus: A target trial emulation study
by: Eric Yuk Fai Wan, et al.
Published: (2024)

Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomised trials
by: Hendra Zufry, et al.
Published: (2025)

Real‐time continuous glucose monitoring improves postoperative glucose control in people with type 2 diabetes mellitus undergoing coronary artery bypass grafting: A randomized clinical trial
by: Heejun Son, et al.
Published: (2025)

Erythropoiesis and estimated fluid volume regulation following initiation of ipragliflozin treatment in patients with type 2 diabetes mellitus and chronic kidney disease: A post‐hoc analysis of the PROCEED trial
by: Tatsuya Maruhashi, et al.
Published: (2024)

Effect of introduction of intermittently scanned continuous glucose monitoring on glycaemic control in individuals living with type 2 diabetes mellitus treated with non‐insulin therapies—A randomised controlled trial
by: Emmanuel Ssemmondo, et al.
Published: (2024)

Efficacy and safety of bi‐weekly cofrogliptin treatment replacing daily dipeptidyl peptidase‐4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open‐label, randomized controlled phase 2 trial
by: Congqing Pan, et al.
Published: (2025)

Efficacy and safety of a tubeless open‐source hybrid automated insulin delivery use at home among adults with type 1 diabetes mellitus: Results from a 26‐week, free‐living, randomized crossover trial
by: Mengyun Lei, et al.
Published: (2025)

Anabolic androgenic steroid use and risk of diabetes mellitus in males
by: Frederik Viggo Lautrup Esmann, et al.
Published: (2025)

Targeted metabolomics reveals novel biomarkers for gestational diabetes mellitus
by: Zhuangfei Xu, et al.
Published: (2025)

Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post‐hoc analysis of the EMMY trial
by: Caren Sourij, et al.
Published: (2024)

Taste perception genomics in gestational diabetes mellitus: A systematic review
by: Vishnu Shivam, et al.
Published: (2024)

Time trends and regional variation in utilization of antidiabetic medicines in China, 2015–2022
by: Jieqiong Zhang, et al.
Published: (2024)

Concerns regarding “ GLP ‐ 1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes”
by: Chien‐Hsiang Weng, et al.
Published: (2025)

Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus
by: Michael S. Kelly, et al.
Published: (2024)

Glucose‐lowering medicines use before and after entry into long‐term care facilities
by: Yohanes A. Wondimkun, et al.
Published: (2024)

Correction to “Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”
Published: (2024)

A systematic literature review on the burden of diabetic ketoacidosis in type 2 diabetes mellitus
by: Carol Wysham, et al.
Published: (2025)

A meta‐analysis of adverse offspring health outcomes in patients with gestational diabetes mellitus
by: Jiewen Guan, et al.
Published: (2025)

Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
by: Jonathan Brix Winther, et al.
Published: (2024)

Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus ( RECAM study)
by: Leili Gao, et al.
Published: (2025)

Natriuretic peptide levels and predicting risk of developing new diabetes mellitus and metabolic syndrome
by: Jasraj Singh, et al.
Published: (2024)

Metabolomic network reveals novel biomarkers for type 2 diabetes mellitus in the UK Biobank study
by: Jiahao Liu, et al.
Published: (2025)

Safety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico
by: Juan Rosas‐Guzman, et al.
Published: (2025)

Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism
by: Nadan Gregorič, et al.
Published: (2024)